CAMXNasdaq StockholmHealth CareIFRS · SEK

Camurus

Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus creates new drug products with best-in-class potential, particularly in the areas of CNS, endocrinology, and oncology. The company operates across Europe, the US, and Australia, and is listed on Nasdaq Stockholm under the ticker CAMX. Camurus is committed to improving patient outcomes through its extensive R&D pipeline and strategic partnerships.

Ask about the company
Revenue2,265m SEK
+21.3 %y/y
Operating profit (EBIT)874m SEK
+86.3 %y/y
EBIT margin38.6%
+13.5 ppy/y
Net income736m SEK
+71.8 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-50005001,0001,5002,0002,500m SEK2021: 601 m SEK2021: EBIT -111 m SEK20212022: 956 m SEK2022: EBIT 72 m SEK20222023: 1,717 m SEK2023: EBIT 526 m SEK20232024: 1,868 m SEK2024: EBIT 469 m SEK20242025: 2,265 m SEK2025: EBIT 874 m SEK20252,265874
RevenueOperating profit (EBIT)
Ask Clarifo about Camurus

Business

Share of revenue
Opioid Dependence Treatments50 %

Includes products like Buvidal® and Brixadi® for treating opioid use disorders.

Endocrinology Treatments25 %

Covers products like Oczyesa® for acromegaly and CAM2029 for endocrine disorders.

Oncology Treatments10 %

Includes pipeline products for cancer treatment.

Obesity and Diabetes Treatments10 %

Involves products like CAM2056 for obesity and diabetes management.

Drug Delivery Technology5 %

FluidCrystal® technology used for drug delivery solutions.

Customers

Camurus serves a diverse range of customers, primarily healthcare providers and pharmaceutical companies. Its products are used by medical professionals treating patients with severe and chronic conditions such as opioid dependence, acromegaly, and other endocrine disorders. The company also collaborates with pharmaceutical companies for the development and distribution of its products. Additionally, Camurus engages with patient advocacy groups and medical experts to support market entry and product adoption.

Healthcare Providers

Purchase products like Buvidal® for treating opioid dependence.

Pharmaceutical Companies

Collaborate on product development and distribution.

Endocrinologists

Use products like Oczyesa® for treating endocrine disorders.

Patient Advocacy Groups

Support treatment adoption and market entry.

Strategy

Camurus focuses on expanding its product portfolio and global market presence through strategic partnerships and innovative R&D. The company aims to leverage its FluidCrystal® technology to develop long-acting medications that improve patient outcomes. Key strategic priorities include the successful launch of new products like Oczyesa® in Europe and Brixadi® in the US. Camurus also seeks to enhance its R&D pipeline with promising candidates like CAM2056 for obesity and diabetes. The company is committed to sustainable profitability and value creation for stakeholders.

Expand Product PortfolioMedium term

To increase market reach and diversify offerings.

Leverage FluidCrystal® TechnologyLong term

To develop innovative long-acting medications.

Successful Product LaunchesShort term

To capture market share and drive revenue growth.

Geography

Q4/2025

Camurus operates internationally with a strong presence in Europe, the US, and Australia. The company's headquarters are located in Lund, Sweden. Europe is a key market, particularly for products like Buvidal® and Oczyesa®, with significant sales in countries like Germany and Sweden. The US market is critical for the launch of new products such as Brixadi®. The company's global operations are supported by strategic partnerships and collaborations to expand its market reach.

Europe37 %
Afrikka, Lähi-itä ja Aasia36 %
North America26 %

Share of the revenue the company reports by geography.

Risks

Camurus faces several business and financial risks, including regulatory risks related to the approval of new drugs and changes in distribution models. Currency fluctuations pose a risk due to the company's international operations. There are also risks associated with R&D, such as clinical trial failures or delays. Additionally, competitive pressures from other pharmaceutical companies and potential IP disputes could impact market position. The company must also manage risks related to strategic partnerships and their execution.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →R&D Failures1Regulatory Approval Delays2Currency Fluctuations3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. R&D FailuresImpact: CriticalLikelihood: Medium

    Could result in sunk costs and lost opportunities.

  2. Regulatory Approval DelaysImpact: HighLikelihood: Medium

    Could delay market entry and revenue generation.

  3. Currency FluctuationsImpact: MediumLikelihood: Low

    Affect financial performance due to international operations.

Ask Clarifo about Camurus

Accounting

Judgemental items
Revenue Recognition

Impacts timing and amount of reported revenue.

Impact: high

Currency Risk

Affects financial performance due to exchange rate fluctuations.

Impact: medium

Share-Based Payments

Influences reported personnel costs and equity.

Impact: medium

Similar listed companies

Publicly listed companies with a comparable business focus.

Bristol-Myers Squibb Company

BMY · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Vicore Pharma Holding AB

VCRE · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Cumberland Pharmaceuticals Inc

CPIX · Pharmaceutical Preparations

Oculis Holding AG

OCS · Pharmaceutical Preparations

Last updated: 24/09/2026

Camurus (CAMX) Revenue, Earnings & Financials 2025 – Clarifo